Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- proteins binding GCN5 nuclear acetyltransferases C-terminal C-terminus acetyl-lysine N-terminal N-terminus histones H3 H4 transcriptional activators MyoD E2F1 p53 acetylates PTEN K125 K128 catalytic cleft in vivo enzymes cancers active genes regulations
- Product Overview:
p300/(CREB binding protein) associated factor (PCAF) belongs to the GCN5/PCAF family of nuclear histone acetyltransferases (HATs).{14390} Gcn5/PCAF proteins contain a ~160 residue HAT domain and a conserved bromodomain directly C-terminal to the HAT domain, which has been shown recently to be an acetyl-lysine targeting motif.{14390,14391} PCAF acetylates specific lysines on the N-terminal tails of Histones H3 & H4 and on the transcriptional activators MyoD, E2F1, and p53. Recently, PCAF was also shown to acetylate PTEN on lysine residues K125 & K128 within the catalytic cleft thus inactivating the enzyme.{14389} In many, but not all of these cases, acetylation has been shown to enhance the DNA binding affinity of the affected protein. Although the recombinant HAT proteins will acetylate free histones, nucleosomal acetylation only occurs in the context of the in vivo HAT complex. Cayman’s PCAF preparation contains 165 amino acids from the HAT activity domain of human PCAF fused to GST at the N-terminus.{14388} Enzyme activity was determined using a fluorescent HAT assay and is comparable to that found in the literature.{14387}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.